Business Context and Reporting Period
Compugen Ltd. (NASDAQ: CGEN), a foreign private issuer based in Tel-Aviv, Israel, reported financial results for the first quarter ended March 31, 2007. The company operates as a discovery engine for therapeutic and diagnostic product candidates, focusing on cancer, immune-related, and cardiovascular diseases. Its primary commercialization strategy involves out-licensing and joint development agreements.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Revenues | $0 | $200,000 |
| Net Loss | $3.1 million | $3.1 million |
| Net Loss Per Share | ($0.11) | ($0.11) |
| Research & Development Expenses (Net) | $2.2 million | $2.3 million |
| Stock-Based Compensation | $821,000 | $547,000 |
| Cash and Marketable Securities | $23.5 million | N/A |
| Total Assets | $28.0 million | N/A |
As of March 31, 2007, the company held $23.5 million in cash, cash equivalents, deposits, and marketable securities. Total operating expenses for the quarter were $3.4 million.
Material Changes Versus Prior Period
- Revenue: Revenues dropped to zero from $200,000 in the prior year quarter, consistent with management projections.
- Net Loss: The net loss remained flat at approximately $3.1 million year-over-year, though the composition of expenses shifted.
- Stock-Based Compensation: Non-cash stock-based compensation increased by $274,000 to $821,000.
- R&D Expenses: Gross R&D expenses decreased by $240,000 to $2.5 million. However, governmental grants also decreased by $120,000 to $297,000, resulting in a net R&D expense decrease of $120,000.
- Liquidity: Cash and marketable securities decreased by $2.9 million from the December 31, 2006 balance of $25.4 million.
Guidance, Outlook, and Management Commentary
Management highlighted significant scientific and commercial milestones, including a co-development agreement with Medarex, collaborations with Teva and Mayo Clinic, and the expansion of an immunoassay diagnostic agreement with Biosite. The CEO attributed productivity to the company's "discovery engine" approach.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks identified include changes in collaborator relationships, competitive pressures, technological changes, and the ability to retain customers. The company relies on milestone and revenue-sharing agreements for commercialization.
Investor Verification Checklist
- Verify the sustainability of the cash burn rate given the $2.9 million quarterly decrease in liquidity and zero revenue generation.
- Confirm the status and potential revenue impact of the newly announced collaborations with Medarex, Teva, and Mayo Clinic.
- Review the specific terms of the governmental grants, as a reduction in these grants directly impacts net R&D expenses.
- Assess the timeline for converting the company's scientific discoveries (e.g., 200,000 genetic variations, 8 novel ligands) into licensed products or revenue.